PNPLA3 rs738409、年龄、糖尿病、性别和晚期纤维化共同影响代谢功能障碍相关脂肪性肝病主要不良肝脏结局风险
研究纳入2075例经活检确诊的MASLD成人,前瞻性随访平均4.3年,记录104例MALO。PNPLA3 G等位基因、晚期纤维化、年龄>60岁和2型糖尿病均与MALO相关;在晚期纤维化者中,G等位基因携带者MALO累积发生率85%,非携带者53%(p=0.03),交互作用p<0.01。
要点
- PNPLA3 G等位基因与MALO风险独立相关(Adj. sHR 1.4,95%CI 1.07-1.8)。
- 晚期纤维化者中G等位基因携带者MALO累积发生率85%,非携带者53%(p=0.03)。
- PNPLA3与MALO的关联在年龄>60岁、女性、晚期纤维化或2型糖尿病者中更强。
核心结论
- PNPLA3 rs738409对MALO风险的不良效应被晚期纤维化、年龄、2型糖尿病和性别显著加重。
研究设计与样本
- 2075例经活检确诊的MASLD成人纳入MASH CRN研究,前瞻性随访至死亡、移植或撤回知情同意,平均随访4.3年。
主要发现
- 随访期间记录104例MALO。
- PNPLA3 G等位基因与MALO相关(Adj. sHR 1.4,95%CI 1.07-1.8)。
- 晚期纤维化与MALO相关(Adj. sHR 7.8,95%CI 4.4-13.8)。
- 年龄>60岁与MALO相关(Adj. sHR 2.9,95%CI 1.3-6.8)。
- 2型糖尿病与MALO相关(Adj. sHR 2.8,95%CI 1.8-4.2)。
关键数值与推荐
- PNPLA3与MALO的关联在年龄>60岁者(sHR 2.1,95%CI 1.5-2.8)强于对照,交互作用p<0.01。
- PNPLA3与MALO的关联在女性(sHR 1.4,95%CI 1.1-1.9)强于对照,交互作用p<0.01。
- PNPLA3与MALO的关联在晚期纤维化者(sHR 1.9,95%CI 1.5-2.4)强于对照,交互作用p<0.01。
- PNPLA3与MALO的关联在2型糖尿病者(sHR 2.1,95%CI 1.5-2.8)强于对照,交互作用p<0.01。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The patatin-like phospholipase domain-containing protein 3 ( PNPLA3 ) rs738409 variant is associated with steatotic liver disease and its progression. We examined the association between PNPLA3 and the development of major adverse liver outcomes (MALOs) and how nonmodifiable and modifiable conditions modify this relationship. APPROACH AND RESULTS: A total of 2075 adults with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) were enrolled in the metabolic dysfunction-associated steatohepatitis Clinical Research Network (MASH CRN) studies and followed prospectively until death, transplant, or withdrawal of consent. One hundred four MALOs were recorded during an average of 4.3 years. PNPLA3 G-allele (Adj. sub-hazard ratio (sHR): 1.4, 95% CI: 1.07-1.8), advanced fibrosis (AF) (Adj. sHR: 7.8, 95% CI: 4.4-13.8), age >60 years (Adj. sHR: 2.9, 95% CI: 1.3-6.8), and type 2 diabetes mellitus (Adj. sHR: 2.8, 95% CI: 1.8-4.2) were associated with MALO. Among participants with AF, those carrying the G-allele displayed the highest cumulative incidence of MALO (85%) versus noncarriers (53%), p =0.03, and p -value for interaction <0.01. The strength of the association between PNPLA3 and MALO was statistically significantly greater among older than 60 years (sHR: 2.1, 95% CI: 1.5-2.8), women (sHR: 1.4, 95% CI: 1.1-1.9), and those with AF (sHR: 1.9, 95% CI: 1.5-2.4) or type 2 diabetes mellitus (sHR: 2.1, 95% CI: 1.5-2.8) as compared with their counterparts, p -value for interaction between PNPLA3 and each factor<0.01. CONCLUSIONS: The deleterious effects of PNPLA3 rs738409 on the risk of MALO are significantly worsened by AF, age, type 2 diabetes mellitus, and sex.
引用
- Chalasani N, Vilar-Gomez E, Loomba R, et al. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024. PMID: 38652636. doi:10.1097/HEP.0000000000000896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。